October Pharma results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements.
Net profit37.05 millionEGP · −27.9% vs the same period a year earlier
Total assets1.41 billionEGP · +24.2% vs the same period a year earlier
Shareholders' equity569 millionEGP · −3.4% vs the same period a year earlier
Operating cash flow80.83 millionEGP · +31.7% vs the same period a year earlier
In short
- October Pharma's net profit for Q4 2024 was about 37.05 million EGP, down −27.9% from 51.39 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 1.41 billion EGP, and shareholders' equity about 569 million EGP.
- Operating cash flow for Q4 2024 was positive at 80.83 million EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit37.05 million51.39 million−27.9%
Gross profit151 million144 million+4.6%
Total assets1.41 billion1.14 billion+24.2%
Total liabilities844 million549 million+53.9%
Shareholders' equity569 million590 million−3.4%
Total liabilities and equity1.41 billion1.14 billion+24.2%
Operating cash flow80.83 million61.37 million+31.7%
Investing cash flow-5.36 million-2.1 million−155.1%
Financing cash flow-70.63 million-40.63 million−73.9%
Net change in cash4.84 million18.64 million−74.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy